News

Atossa Genetics Announces Preliminary Results from Male Phase 1 Study of Topical Endoxifen – Nasdaq

[ad_1]


Fairfield Current

Atossa Genetics Announces Preliminary Results from Male Phase 1 Study of Topical Endoxifen
Nasdaq
“Based on these positive preliminary results, we are advancing our topical Endoxifen into a Phase 2 study to reduce gynecomastia in men starting prostate cancer therapy,” commented Dr. Steven C. Quay, CEO and President. “We anticipate retaining a
Maxim Stays Bullish on Atossa (ATOS) Stock Following Preliminary Phase 1 ResultsSmarter Analyst

all 17 news articles »

[ad_2]
Source link

About the author

admin

Add Comment

Click here to post a comment

Health Motivation

Advertise

Recent Post

Advertise